Custom Health (CHLT) Q1 2026 earnings summary

Executive summary

• Achieved consolidated Q1 2026 revenue of $12.9M, with Custom Health contributing $4.3M and InnovativeRx $8.6M.

• Completed public listing on the Toronto Stock Exchange, enhancing capital markets access and liquidity.

• Strategic acquisition of InnovativeRx expands operational footprint and accelerates integration onto the AdhereNet® platform.

• Leadership team strengthened with key appointments in compliance, regulatory, and corporate development.

Financial highlights

• Custom Health Q1 2026 revenue rose 5% year-over-year to $4.3M; gross profit increased 14% to $2.1M.

• Gross margin improved to 48.6% from 44.8% in Q1 2025.

• Adjusted EBITDA loss widened to $5.3M from $3.0M year-over-year; IFRS net loss from continuing operations was $8.5M, up from $7.3M.

• InnovativeRx Q2 2026 revenue grew 10.5% year-over-year to $8.6M, with positive Adjusted EBITDA of $0.6M.

• Proforma annualized revenue run-rate reached $51.6M.

Outlook and guidance

• Positioned for sustained growth through expanded pharmacy network, capital strength, and AI-enabled clinical workflows.

• Focus remains on disciplined execution, measurable outcomes, and long-term shareholder value.